Prothena Q2 FY26 net loss narrows to $18.6 million; revenue drops to $1 million

Reuters2026/08/06 20:22

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Prothena posted a Q2 net loss of USD 18.6 million, narrowing from a USD 125.8 million loss a year earlier; revenue fell to USD 1 million from USD 4.4 million.
First-half results swung to net income of USD 14.1 million from a loss of USD 186 million; revenue rose to USD 52.1 million from USD 7.2 million.
RD expense dropped to USD 8.8 million from USD 40.5 million; GA declined to USD 10.9 million from USD 15.9 million.
Cash, cash equivalents and restricted cash totaled USD 289.1 million at June 30, 2026; net cash used in operating and investing activities was USD 25.7 million in Q2.
Guidance targets year-end cash of about USD 259 million (midpoint); Roche PADOVA results for prasinezumab were published in The Lancet, with Phase 3 PARAISO primary completion expected in 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202608061605BIZWIRE_USPR_____20260806_BW855960) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Prothena Q2 FY26 net loss narrows to $18.6 million; revenue drops to $1 million

You may also like

Crypto prices